http://www.onemedplace.com/blog The one place to find the companies, technologies and ideas shaping the future of healthcare Sun, 21 Mar 2010 17:40:47 +0000 http://backend.userland.com/rss092 en Insomnia isn't just the inability to go to sleep. Sufferers may finally drift into slumber, only to wake up too early and be unable to go back to sleep. They may also wake frequently during the night. These symptoms, termed sleep maintenance difficulty, are the most common symptom of insomnia. This week, the U.S. ... http://www.onemedplace.com/blog/archives/4603 On Thursday, the U.S. Food and Drug Administration unveiled a new initiative to accelerate the development of cocktail drugs to treat tuberculosis (TB). A number of pharmaceutical companies will collaborate with FDA scientists to test new TB combination therapies and identify promising candidates. The program, called Critical Path to TB Drug Regimens ... http://www.onemedplace.com/blog/archives/4491 The Harvard Business Review recently published a list of 10 innovations poised to change the medical industry in 2010. Among flashier inclusions such as surgical robots and virtual doctor's visits, accountable care organizations (ACOs)  may not sound very exciting. But the concept is picking up momentum amid the healthcare reform debate. ... http://www.onemedplace.com/blog/archives/4596 Last month, the U.S. Food and Drug Administration called for better controls on medical radiation exposure. Patients undergoing diagnostic scans or medical treatments may be exposed to toxic levels of radiation, as may the physicians who treat them. Cath labs are known to be particularly hazardous when it comes to ... http://www.onemedplace.com/blog/archives/4589 The 2003 death of Three's Company actor John Ritter created new public awareness of aortic dissection, a condition that affects tens of thousands of Americans each year. Aortic dissection occurs when the wall of the aorta, the body’s main blood vessel, splits.  Blood flows into the aortic wall and travels down ... http://www.onemedplace.com/blog/archives/4564 Shares in InterMune soared this week after a U.S. Food and Drug Administration panel recommended approval for the company's lung-disease treatment. The recommendation caused a 64 percent jump in InterMune stock prices and fueled speculation that the Brisbane, Calif.-based company is ripe for acquisition. InterMune of Brisbane, Calif., is developing pirfenidone ... http://www.onemedplace.com/blog/archives/4567 By Mike Havrilla, MikeHavRx.com HavRx Global Crop Science Index: Potash (NYSE: POT) is poised to open trading at new highs after posting strong earnings and upping its guidance. Meanwhile, Yara International (OTC: YARIY.PK) has withdrawn its bid for Terra Industries (NYSE: TRA), which will be acquired by CF Industries (NYSE: CF). ... http://www.onemedplace.com/blog/archives/4559 BioSante Pharmaceuticals may be known for its sexual health products such as LibiGel, but the Illinois-based company is also developing a novel immunotherapy vaccine to treat cancer. The company announced Wednesday that its GVAX Leukemia Vaccine demonstrated the ability to reduce or eliminate the last remaining cancer cells in patients with ... http://www.onemedplace.com/blog/archives/4496 Cytokinetics, a biotechnology company developing small molecule therapeutics for multiple diseases, has been granted orphan drug status by the U.S. Food and Drug Administration for its drug candidate to treat amyotrophic lateral sclerosis, or Lou Gehrig's disease. The San Francisco-based company plans to start a Phase II clinical trial of the ... http://www.onemedplace.com/blog/archives/4492 It is often difficult to understand why a patient may develop terminal cancer, or why one patient responds to a particular medication while another doesn't. The concept of personalized or translational medicine, which has been gaining popularity in recent years, seeks to answer questions such as these. Instead of a one-size-fits-all approach to treatment, ... http://www.onemedplace.com/blog/archives/4388